Glenmark’s Remogliflozin Hopes To Shake Up Indian SGLT2i Market
Executive Summary
Glenmark’s remogliflozin is priced about 50% lower than the other SGLT2 inhibitors in India and is expected to expand access to the class of drugs significantly. Early physician outlook for the new SGLT2 inhibitor appears encouraging.
You may also be interested in...
Glenmark Readies New Diabetes Combo In India
Glenmark is working on a combination of remogliflozin and teneligliptin in India, which if successful could bring additional sting to its portfolio in the country's bustling diabetes segment. But Boehringer-Lilly’s rival Glyxambi already has a head-start.
Deal Watch: Pfizer Licenses Skin-Targeted JAK Inhibitor Portfolio From Theravance
Deal with Pfizer makes for Theravance’s third large pharma partnership since 2016. AbbVie off-loads Marinol to India’s Alkem, Bausch licenses candidate for rare form of dry eye disease from Novaliq.
Newbie Remogliflozin Gives Competition A Run For Their Money
Remogliflozin prescriptions gallop in India and Glenmark expects the ‘affordable’ therapy to take share from other SGLT2 inhibitors.
Need a specific report? 1000+ reports available
Buy Reports